Melatonergic antidepressant agomelatine: augmentation of antipsychotic drugs in treatment of post-schizophrenic depression

Ivanov S.V.

doi:https://doi.org/10.17116/jnevro20241240815

Close metadata

Recommended articles:

Asthenia in the acute period of ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3-2):5-10

The state of mental health of migrant workers and citizens of the Russian Federation: A comparative analysis as illustrated by the Moscow region. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):95-101

Factors of depression according to actigraphy in the fall season. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5-2):27-32

Analysis of cognitive status in patients with different nosologies and clinical variants of very late manifesting schizophreniform psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):88-93

Identification of depression biomarkers: Prospects for use in clinical practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):51-55

Depression Anxiety Stress Scale (russian language version). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):103-107

Investigation of the relationship of individual characteristics of the brain bioelectrical activity with levels of mental stress, aggression, anxiety, and depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):108-117

Modern concepts of sleep disturbances associated with mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):7-12

Association of cortisol levels with psychopathological features of depression and therapeutic response in female patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):45-54

Gender characteristics of cardiovascular diseases psychosocial risk factors associations with sleep quality in an open urban population. Russian Journal of Preventive Medicine. 2025;(6):67-73

Abstract:

The article presents an analytical review of the data on the effectiveness of agomelatine as an augmentation of antipsychotics in the treatment of post-schizophrenic depression (PSD). The results of 5 published studies with a total sample size of 137 patients, the duration of therapy from 28 to 180 days with the appointment of agomelatin in combination with antipsychotics, including cases of additional use of drugs of other classes (normotimics, antidepressants, anxiolytics, anticholinergic correctors) were used. As a result, a pronounced effect was established in the indicators of respondents and patients in remission, combined with a favorable tolerability and safety profile, determining the prospects for the use of agomelatin in the therapy of PSD. Certain limitations in the methodology, including open and uncontrolled research design and small sample sizes, determine the relevance of systematic controlled trials to confirm the results obtained.

Keywords:

schizophrenia

depression

post-schizophrenic depression

antidepressants

agomelatine

Authors:

Ivanov S.V.

Mental Health Research Center

ORCID: 0000-0001-9532-7150

Received:

30.07.2024

Accepted:

31.07.2024

Close metadata

References:

Siris SG. Depression in schizophrenia: perspective in the era of «Atypical» antipsychotic agents. Am J Psychiatry. 2000;157(9):1379-1389. https://doi.org/10.1176/appi.ajp.157.9.1379
Owens DG, Johnstone EC. Precursors and prodromata of schizophrenia: findings from the Edinburgh High Risk Study and their literature context. Psychol Med. 2006;36(11):1501-1514. https://doi.org/10.1017/S0033291706008221
Häfner H, Maurer K, Trendler G, et al. Schizophrenia and depression: challenging the paradigm of two separate diseases —a controlled study of schizophrenia, depression and healthy controls. Schizophr Res. 2005;77(1):11-24. https://doi.org/10.1016/j.schres.2005.01.004
Upthegrove R, Birchwood M, Ross K, et al. The evolution of depression and suicidality in first episode psychosis. Acta Psychiatr Scand. 2010;122(3):211-218. https://doi.org/10.1111/j.1600-0447.2009.01506.x
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th text revision. Washington, DC 2000.
American Psychiatric Association, 2013. Diagnostic and statistical manual of mental disorders (5th ed.). American Journal of Psychiatry. 2013.
Siris SG. Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull. 1991;17(1):75-98. https://doi.org/10.1093/schbul/17.1.75
Rooske O, Birchwood M. Loss, humiliation and entrapment as appraisals of schizophrenic illness: a prospective study of depressed and non-depressed patients. Br J Clin Psychol. 1998;37(3):259-268. https://doi.org/10.1111/j.2044-8260.1998.tb01384.x
Birchwood M, Iqbal Z, Chadwick P, et al. Cognitive approach to depression and suicidal thinking in psychosis. 1. Ontogeny of post-psychotic depression. Br J Psychiatry. 2000;177:516-521. https://doi.org/10.1192/bjp.177.6.516
Harvey RC, James AC, Shields GE. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia. CNS Drugs. 2016;30(1):27-39. https://doi.org/10.1007/s40263-015-0308-1
Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394(10202):939-951. https://doi.org/10.1016/S0140-6736(19)31135-3
Dollfus S, Olivier V, Chabot B, et al. Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. Schizophr Res. 2005;78(2-3):157-159. https://doi.org/10.1016/j.schres.2005.06.001
Biswas T, Mishra BR, Maiti R, et al. Efficacy and safety of low-dose amisulpride versus olanzapine-fluoxetine combination in post-schizophrenic depression: A randomized controlled trial. J Psychiatr Res. 2024;173:302-308. https://doi.org/10.1016/j.jpsychires.2024.03.048
Rybakowski JK, Vansteelandt K, Szafranski T, et al; EUFEST Study Group. Treatment of depression in first episode of schizophrenia: results from EUFEST. Eur Neuropsychopharmacol. 2012;22(12):875-882. https://doi.org/10.1016/j.euroneuro.2012.04.001
Riedel M, Mayr A, Seemüller F, et al. Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol. World J Biol Psychiatry. 2012;13(1):30-38. https://doi.org/10.3109/15622975.2011.552633
Helfer B, Samara MT, Huhn M, et al. Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. Am J Psychiatry. 2016;173(9):876-886. https://doi.org/10.1176/appi.ajp.2016.15081035
Gregory A, Mallikarjun P, Upthegrove R. Treatment of depression in schizophrenia: systematic review and meta-analysis. Br J Psychiatry. 2017;211(4):198-204. https://doi.org/10.1192/bjp.bp.116.190520
Bodoano Sánchez I, Mata Agudo A, Guerrero-Jiménez M, et al. Treatment of post-psychotic depression in first-episode psychosis. A systematic review. Nord J Psychiatry. 2023;77(2):109-117. https://doi.org/10.1080/08039488.2022.2067225
Taylor D, Sparshatt A, Varma S, et al. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014;348:g1888. Erratum in: BMJ. 2014;348:g2496. https://doi.org/10.1136/bmj.g1888
Poletskiy VM, Kolmogorova VV, Kurkin SD, et al. Agomelatine in therapy post-schizophrenia depression. Psychiatry and Psychopharmacotherapy P.B. Gannushkin. 2013;02:16-22. (In Russ.). https://con-med.ru/magazines/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina-02-2013/valdoksan_v_terapii_postshizofrenicheskikh_depressiy/
Panteleeva GP, Abramova LI, Novozhenova TE, et al. Clinical-psychopathological aspects of therapeutic effects of agomelatine (valdoxan) and its place in perfection of methods of therapy of postschizophrenic depressive disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(3):59-69. (In Russ.). https://doi.org/10.17116/jnevro20181183159-69
Petrova NN. To the question of the treatment of depression in patients with schizophrenia. Psychiatry and Psychopharmacotherapy P.B. Gannushkin. 2014;02:25-28. (In Russ.). https://con-med.ru/magazines/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina-02-2014/k_voprosu_o_terapii_depressii_u_bolnykh_shizofreniey/
Sofronov AG, Spikina AA, Rylskaia OV. The effectiveness of agomelatine in the treatment of patients with schizophrenia and comorbid depressive symptoms. Psychiatry and Psychopharmacotherapy P.B. Gannushkin. 2016;18(5):22-28. (In Russ.). https://con-med.ru/magazines/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina/psikhiatriya_i_psikhofarmakoterapiya_im_p_b_ganushkina-05-2016/effektivnost_valdoksana_v_kompleksnoy_terapii_bolnykh_shizofreniey_s_soputstvuyushchey_depressivnoy_/
Englisch S, Jung HS, Lewien A, et al. Agomelatine for the Treatment of Major Depressive Episodes in Schizophrenia-Spectrum Disorders: An Open-Prospective Proof-of-Concept Study. J Clin Psychopharmacol. 2016;36(6):597-607. https://doi.org/10.1097/JCP.0000000000000587
Mutschler J, Rüsch N, Schönfelder H, et al. Agomelatine for Depression in Schizophrenia: A Case-Series. Psychopharmacol Bull. 2012;45(1):35-43.
Morera-Fumero AL, Abreu-Gonzalez P. Diazepam discontinuation through agomelatine in schizophrenia with insomnia and depression. J Clin Psychopharmacol. 2010;30(6):739-741. https://doi.org/10.1097/JCP.0b013e3181fbbb7d
Ахметгареева Р.Р. Препарат агомелатин при депрессивных расстройствах и нарушения сна у пациента с диагнозом параноидная шизофрения. Материалы научно-практической конференции студентов и молодых ученых Инновации в медицине и фармации. Минск, БГМУ, 2018;54-57.
Ahmetgareeva RR. Agomelatine drug in depressive disorders and sleep disturbance in patient with paranoid schizophrenia diagnosis. Materials of «Innovation in medicine and pharmacy» research and practice conference of students and young scientists. Minsk, BGMU, 2018;54-57. (In Russ.).
Bardenshtejn LM, Krahoveckaja DS, Shherbakova IV, Krupkin AG. Comparative effectiveness assessment of seasonal affective disorder treatment in patients with schizotypal disorder. Issues of theory and clinical practice in psychiatry, addictology and psychotherapy: Materials of the II research and practice conference with international participation. Tjumenskij medicinskij zhurnal. 2012;1:6-7. (In Russ.).
Bruno A, Zoccali RA, Abenavoli E, et al. Augmentation of clozapine with agomelatine in partial-responder schizophrenia: a 16-week, open-label, uncontrolled pilot study. J Clin Psychopharmacol. 2014;34(4):491-494. https://doi.org/10.1097/JCP.0000000000000157
Zimmerman M, Martinez JH, Young D, et al. Severity classification on the Hamilton Depression Rating Scale. J Affect Disord. 2013;150(2):384-388. https://doi.org/10.1016/j.jad.2013.04.028